
InSphero
Total Raised
$38.83MInvestors Count
17Deal Terms
2Funding, Valuation & Revenue
16 Fundings
InSphero has raised $38.83M over 16 rounds.
InSphero's latest funding round was a Grant - VI for on November 18, 2024.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
11/18/2024 | Grant - VI | 2 | ||||
8/19/2024 | Grant - V | 3 | ||||
3/31/2023 | Unattributed VC | ZEISS Ventures, and Undisclosed Investors | 2 | |||
1/20/2023 | Grant - IV | |||||
9/17/2019 | Incubator/Accelerator |
Date | 11/18/2024 | 8/19/2024 | 3/31/2023 | 1/20/2023 | 9/17/2019 |
|---|---|---|---|---|---|
Round | Grant - VI | Grant - V | Unattributed VC | Grant - IV | Incubator/Accelerator |
Amount | |||||
Investors | ZEISS Ventures, and Undisclosed Investors | ||||
Valuation | |||||
Revenue | |||||
Sources | 2 | 3 | 2 |
InSphero Deal Terms
2 Deal Terms
InSphero's deal structure is available for 2 funding rounds, including their Series B from June 18, 2013.
Round | Series B | Series A |
|---|---|---|
Funding Date | ||
Pre-Money Valuation | ||
Post-Money Valuation | ||
Amount Raised | ||
Shares Authorized | ||
Issuance Price | ||
Dividend Rate | ||
Liquidation Preferences | ||
Liquidation Price | ||
Participation | ||
Conversion Price | ||
Anti Dilution | ||
General Voting | ||
Board Voting | ||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series B | |||||||||||||||
Series A |
InSphero Investors
17 Investors
InSphero has 17 investors. European Union invested in InSphero's Grant - VI funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
11/18/2024 | 11/18/2024 | 1 Grant - VI | Government | Belgium | ||
8/19/2024 | 8/19/2024 | 1 Grant - V | Non-Profit Foundation | New York | ||
3/31/2023 | 3/31/2023 | 1 Unattributed VC | Corporate Venture | Germany | ||
Government | Belgium | |||||
Corporation | Netherlands |
First funding | 11/18/2024 | 8/19/2024 | 3/31/2023 | ||
|---|---|---|---|---|---|
Last Funding | 11/18/2024 | 8/19/2024 | 3/31/2023 | ||
Investor | |||||
Rounds | 1 Grant - VI | 1 Grant - V | 1 Unattributed VC | ||
Board Seats | |||||
Type | Government | Non-Profit Foundation | Corporate Venture | Government | Corporation |
Location | Belgium | New York | Germany | Belgium | Netherlands |
InSphero Acquisitions
1 Acquisition
InSphero acquired 1 company. Their latest acquisition was Doppl on November 11, 2025.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
11/11/2025 | Debt | $0.68M | Acquired | 4 |
Date | 11/11/2025 |
|---|---|
Investment Stage | Debt |
Companies | |
Valuation | |
Total Funding | $0.68M |
Note | Acquired |
Sources | 4 |
Compare InSphero to Competitors

Emulate specializes in advanced in vitro models for research and development in the biotechnology sector. The company offers a human emulation system that includes instruments, consumables, and software designed to mimic human biology and predict human responses to various stimuli. Emulate's technology is primarily utilized in the fields of drug development and disease research. It was founded in 2014 and is based in Boston, Massachusetts.

Stemnovate focuses on drug discovery in the pharmaceutical industry. It has a drug discovery platform that uses multi-organ modelling to evaluate the metabolism and toxicity of drug molecules, to improve clinical trials and patient safety. Stemnovate also offers services including biobanking, cellular reprogramming, and computational modelling to aid in drug development and precision medicine. It was founded in 2016 and is based in Cambridge, United Kingdom.
TissUse is a biotechnology company that develops a 'Multi-Organ-Chip' technology platform for preclinical testing in the pharmaceutical sector. The company provides products that simulate the activity of multiple human organs for research and development purposes, to predict drug toxicity, absorption, distribution, metabolism, and excretion (ADME) profiles, and efficacy in vitro. TissUse serves sectors involved in drug development, cosmetics, food and nutrition, and consumer products. It was founded in 2010 and is based in Berlin, Germany.

MIMETAS focuses on human tissue models for drug discovery within the biotechnology sector. The company provides a platform for creating organ-on-a-chip models that replicate human tissues and disease biology to aid in drug efficacy and safety testing. MIMETAS primarily serves the pharmaceutical industry, supporting research and development in therapeutic areas including oncology, immunology, and neurology. It was founded in 2013 and is based in Leiden, Netherlands.

28bio specializes in neurotechnology engineering human brain models for the neuroscience sector. The company provides a platform that combines tissue engineering, neural interfacing, and artificial intelligence to develop models with functions like memory, learning, and cognition. It serves the biopharmaceutical industry, offering tools for drug discovery and development. 28bio was formerly known as AxoSim Technologies. It was founded in 2014 and is based in New Orleans, Louisiana.

React4Life is a biotech company involved in preclinical research technologies within the biotech and pharmaceutical sectors. They provide MIVO technology, an organ-on-chip system that simulates human biology for drug testing and personalized medicine. The company's services involve laboratory integration of their technology and the development of specific assays for research. It was founded in 2016 and is based in Genova, Italy.
Loading...

